Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1678258

registered interest
date	14/12/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what recent progress her Department has made on strengthening the life sciences sector.
tabling member constituency	Crewe and Nantwich
tabling member printed	Dr Kieran Mullan
uin	7151
answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>Recent progress to strengthen the life sciences sector includes a raft of new initiatives and funding announced at the Autumn Statement. These include £520 million for life sciences manufacturing; £51 million for Our Future Health; the launch of a Rare Therapies Launch Pad; and £10 million of investment in a Centre of Excellence in Oligonucleotide Manufacturing Innovation. Additionally, the government has recently published the full response to the Commercial Clinical Trials Review. These announcements build on the £650 million growth package announced in May and reaffirm the government’s commitment to supporting a thriving life sciences sector.</p> answering member constituency Arundel and South Downs answering member printed Andrew Griffith question first answered 19/12/2023 16:46:48 answering member 4874 label Biography information for Andrew Griffith
tabling member	4860 label Biography information for Dr Kieran Mullan

1652112

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, with reference to her speech at the Creating a Scientific Superpower Conference on 28 June 2023, what the substantial progress is that her Department has made towards realising its ambitious Life Sciences Vision.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193396
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>In the two years since its publication, substantial progress has been made in delivering the ambition of the Vision, including the publication of the Genome UK Implementation Plan, alongside £175 million for cutting edge genomic research.</p><p> </p><p>Most recently, on 26 May, we announced a £650 million policy package that will support several key areas of the life sciences sector, including clinical trials, biomanufacturing, and skills, and drive economic growth. This month, we have also signed a landmark agreement with BioNTech SE which will provide up to 10,000 UK patients with innovative precision cancer immunotherapies by 2030.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 09:56:19 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1651596

registered interest
date	10/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has contingency plans for the life sciences industry should negotiations on the new Voluntary Scheme for branded medicines pricing and access not be concluded.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	193197
answer	answer is ministerial correction date of answer 13/07/2023 answer text <p>The Government is firmly committed to driving growth and investment in the Life Sciences sector while helping to get innovative drugs and medicines to National Health Service patients faster, including through the delivery of the Life Sciences Vision.</p><p>The current voluntary scheme for branded medicines pricing and access (VPAS) finishes at the end of this year. Negotiations on a successor scheme began in May and aim to conclude later this year to take effect from January 2024. We are open to ideas about how a successor VPAS should operate from 2024 onwards and look forward to working with industry to agree a mutually beneficial scheme that supports better patient outcomes, ensures the sustainability of NHS spend on branded medicines and enables a strong United Kingdom life sciences industry.</p><p> </p><p>We cannot comment on ongoing commercially sensitive negotiations.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 193198 question first answered 13/07/2023 09:30:35 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1649381

registered interest
date	30/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps with (a) the Cystic Fibrosis Trust and (b) other patient organisations to implement his Department's Life Sciences Vision.
tabling member constituency	North East Fife
tabling member printed	Wendy Chamberlain
uin	191959
answer	answer is ministerial correction date of answer 06/07/2023 answer text <p>The Office for Life Sciences engage with patient representative organisations to deliver on ambitions in the Life Sciences Vision, including the healthcare missions and genomics. On cystic fibrosis specifically, we will soon be consulting the United Kingdom clinical trials community, individual medical research charities and the Association of Medical Research Charities, of which the Cystic Fibrosis Trust is a member, to implement the headline commitments and inform a full response to the independent Lord James O’Shaughnessy review into UK clinical trials.</p> answering member constituency Colchester answering member printed Will Quince question first answered 06/07/2023 10:46:49 answering member 4423 label Biography information for Will Quince
tabling member	4765 label Biography information for Wendy Chamberlain

1644879

registered interest
date	14/06/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Life Sciences
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the link between (1) their ability to deliver the Life Sciences Vision, including the ambitions to grow the life sciences sector, and (2) the rebates imposed on companies through the Voluntary Scheme for Branded Medicines Pricing and Access.
tabling member printed	Lord Clement-Jones
uin	HL8483
answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The Department for Science, Innovation and Technology (DSIT) work closely with stakeholders across the sector to ensure we deliver the Life Sciences Vision. Supporting the life sciences industry and future innovation is an objective of the voluntary scheme for branded medicines pricing and access (VPAS), and DSIT is working with DHSC to understand how VPAS has impacted investment and innovation in the UK. The Government has considered in broad terms the link between volume-based rebate payments and various kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which operates alongside VPAS.</p><p> </p> answering member printed Viscount Camrose question first answered 26/06/2023 14:10:37 answering member 4939 label Biography information for Viscount Camrose
tabling member	3396 label Biography information for Lord Clement-Jones

1488071

registered interest
date	11/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what further steps he is taking to promote the UK as a global life sciences superpower.
tabling member constituency	Kirkcaldy and Cowdenbeath
tabling member printed	Neale Hanvey
uin	33948
answer	answer is ministerial correction date of answer 26/07/2022 answer text <p><strong> </strong></p><p>The Department’s forthcoming Medtech Strategy will set out further actions to promote competition, transparency and innovation and the United Kingdom’s life sciences sector.</p><p>It will align with the Life Science Vision, which prioritised building capability in research and development, supporting the role of the National Health Service in innovation and creating a business environment which encourages investment in life sciences.</p><p> </p><p>In addition, the Department and the Medicines and Health products Regulatory Agency will implement regulatory reforms to enable the early adoption of innovative medical devices and treatments and enhance the attractiveness of the UK as a place to do business.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 26/07/2022 16:28:47 answering member 3992 label Biography information for James Morris
tabling member	4782 label Biography information for Neale Hanvey

1420093

registered interest
date	07/02/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department has taken on the delivery of the Life Sciences Vision including enabling cancer immune therapies.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	119575
answer	answer is ministerial correction date of answer 15/02/2022 answer text <p>The Government, NHS and Life Science Sector have already taken significant steps in delivering the Life Science Vision. Activity since publication includes the establishment and delivery of the Life Science Scale Up Taskforce, the launch of the £200m Life Sciences Investment Programme, work to improve the NHS’s capacity and capability to utilise new technologies, and innovation work by the Vaccine Taskforce and Antivirals Taskforce to secure access to cutting-edge new technologies to address COVID-19.</p><p> </p><p>Following the conclusion of the 2021 Spending Review on 27th October, the government has confirmed specific funds will be provided upfront to directly support the delivery of the Life Sciences Vision. This includes £95m funding to support the uptake of innovative drugs and technologies and address a number of the Healthcare Missions outlined in the Vision, funding to drive new initiatives through Genomics England to deliver life-changing technologies, and £354m to strengthen the UK’s Life Sciences manufacturing base. This builds on significant programmes of investment in Health Research across DHSC and BEIS, and the largest ever increases in the NHS’s operating budget.</p><p> </p><p>The Office for Life Sciences are working with partner organisations to develop the implementation plan, which will deliver on the commitments as set out in the Life Sciences Vision including supporting the development and commercialisation of immuno-oncology and cancer vaccines in the UK. Further details on the implementation plan will be set out in due course.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/02/2022 15:42:34 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

1420617

registered interest
date	07/02/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 3 February 2022 to Question 114739 on Life Sciences, whether details of the funding will be broken by (a) disease, (b) geographic region and (c) research body; and when he plans to announce how funding for those Research and Development budgets will be allocated.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	119563
answer	answer is ministerial correction date of answer 14/02/2022 answer text <p>Further details of how this funding will be allocated will be announced in due course.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/02/2022 13:09:58 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1418454

registered interest
date	31/01/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy of 11 January 2022, Official Report, column 415, what progress he has made on allocating the dementia research and development budget.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	114739
answer	answer is ministerial correction date of answer 03/02/2022 answer text <p>The Department for Health &amp; Social Care will invest £375 million in neurodegenerative disease research over the next five years to fund projects into a range of diseases including dementia.</p><p> </p><p>Following the Spending Review, the Department for Business, Energy &amp; Industrial Strategy is currently working to set detailed R&amp;D budgets through to 2024/25. Further details of how this funding will be allocated will be announced in due course.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/02/2022 13:49:24 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1402036

registered interest
date	11/01/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to his oral Answer of 11 January 2022, Official Report, column 413, that the life science sector has grown, in terms of private investment, by 1,000 per cent in the last ten years and is creating jobs all around the UK, in Northern Ireland, Scotland, Wales, what the evidential basis is for that answer.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	101716
answer	answer is ministerial correction date of answer 14/01/2022 answer text <p>Analysis conducted by the Office for Life Sciences using data from S&amp;P Capital IQ showed that in the first 10 months of 2021, UK Life Sciences companies raised a total of £6.6bn in equity finance. This is an increase of 1,000% since 2012 when the equivalent figure was £0.6bn. These figures include public and private investment and cover the sectors of Biotechnology, Pharmaceuticals, Life Sciences Tools and Services, Health Care Equipment and Supplies and Health Care Technology. They were set out in the <a href="https://www.gov.uk/government/news/uk-life-sciences-industry-sees-nearly-half-billion-investment-as-pm-convenes-biopharmaceutical-industry-leaders-to-strengthen-future-pandemic-response" target="_blank">press release</a> accompanying the recent Biopharmaceutical CEO Roundtable, held on 2 December 2021.</p><p> </p><p>The <a href="https://www.gov.uk/government/statistics/bioscience-and-health-technology-sector-statistics-2020" target="_blank">2020 Biosciences and Health Sector Statistics publication</a> shows that net employment in the UK life sciences industry increased by 31,500 between 2011 and 2020, and that during that period, net employment increased in England, Scotland, Wales and Northern Ireland.</p><p> </p><p> </p><p><em>Annex: Supporting Data</em></p><table><tbody><tr><td><p><strong>Region</strong></p></td><td><p><strong>Net change in employment between 2011 and 2020</strong></p></td></tr><tr><td><p>London</p></td><td><p>8,200</p></td></tr><tr><td><p>East of England</p></td><td><p>4,900</p></td></tr><tr><td><p>South East</p></td><td><p>4,500</p></td></tr><tr><td><p>Yorkshire and the Humber</p></td><td><p>4,000</p></td></tr><tr><td><p>North West</p></td><td><p>2,500</p></td></tr><tr><td><p>Northern Ireland</p></td><td><p>2,200</p></td></tr><tr><td><p>Wales</p></td><td><p>1,700</p></td></tr><tr><td><p>North East</p></td><td><p>1,700</p></td></tr><tr><td><p>South West</p></td><td><p>1,500</p></td></tr><tr><td><p>East Midlands</p></td><td><p>800</p></td></tr><tr><td><p>Scotland</p></td><td><p>400</p></td></tr><tr><td><p>West Midlands</p></td><td><p>-800</p></td></tr><tr><td><p><strong>Total</strong></p></td><td><p><strong>31,500</strong></p></td></tr></tbody></table><p><em>Source: Office for Life Sciences: Bioscience and Health Technology Statistics 2020</em></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/01/2022 11:23:45 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah